MERRLINNCT04736381
Impact of the Microbiota on the Likelihood of Renal Graft Rejection
StatusCompleted
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Notable Primary completion moved earlier from Jan 7, 2027 to Apr 8, 2025
- Enrollment closed, study ongoing
- Study completion moved earlier from Jan 7, 2027 to Oct 9, 2026
- Study sites: 9 to 10
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates pushed to Jan 7, 2027
- Start date changed from estimate of Apr 14, 2021 to Oct 7, 2021
- Study sites: 0 to 9
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Acute rejection occurence
Timeframe: 1 year or rejection
Secondary (3)
Gut and circulating microbiota
Lymphocyte phenotype
Glomerular filtration rate
Arms and interventions
Kidney transplanted patients treated with Nulojix
Patients treated with Simulect as induction, and with Nulojix®, mycophenolic acid and steroids as maintenance therapy during the first year of kidney transplant.
Drugs: Belatacept Injection [Nulojix]
Sites
10 sites in 1 country